Cymbalta for chronic pain
Eli Lilly submits supplemental new drug application in the second quarter for Cymbalta (duloxetine) in the management of chronic pain, the firm announces May 29. With an expected 10-month review, the drug's likely PDUFA timeframe would be February to March 2009. The drug was approved for acute and maintenance treatment of major depressive disorder Nov. 30; it is also approved for acute treatment of generalized anxiety disorder and management of diabetic peripheral neuropathic pain, all in adults 18 and older. An sNDA for use of the drug in fibromylagia is under FDA review, with an expected PDUFA data in June
You may also be interested in...
Agency must plan to ensure that a growing backlog of surveillance inspections does not impede its ability to conduct inspections at high-risk sites, GAO official says.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.